Skip to main content
TipRanks
Go Ultimate75% OFF

Invex Therapeutics Ltd. (IXC) AI Stock Analysis

2 Followers
AU:IXC

Invex Therapeutics Ltd.

(ASX:IXC)

Select Model
Rating:41Neutral
Price Target:AUD 0.08â–¼(-4.71% Downside)
Action:reiterated
Date:10/27/26

The overall score of 41 reflects a high-risk, distressed biotechnology company. The most significant factor is the dire financial performance, characterized by zero revenue, persistent cash burn, and a rapidly shrinking equity base, which heavily weights the score downward. Valuation is equally poor due to negative earnings. The only modestly positive signal comes from the technical analysis, where the stock price trades above its major moving averages, but this is insufficient to offset the severe fundamental weaknesses.

Positive Factors
Debt-free balance sheetA debt-free balance sheet lowers financial risk by avoiding mandatory interest payments and refinancing exposure. This gives Invex greater flexibility to direct available resources toward development activities and provides a stronger foundation for managing volatility than a similarly loss-making company carrying material leverage.
Negative Factors
Unstable revenue and continuing lossesUnstable revenue and recurring operating and net losses show that Invex has not yet established dependable commercial earnings. The reported zero revenue in 2026 reinforces the early-stage nature of the business and leaves future progress reliant on successful development, approval, and eventual market adoption of its therapy.

Invex Therapeutics Ltd. (IXC) vs. iShares MSCI Australia ETF (EWA)

-30%-20%-10%0%10%20%30%AU:IXC-29.17%EWA+16.41%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 7.60M
Dividend Yield
―
Average Volume (3M)
79.68K
Price to Earnings (P/E)
-4.7
Beta (1Y)
0.17
Revenue Growth
―
EPS Growth
-185.71%
Country
Australia
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Invex Therapeutics Ltd. Business Overview & Revenue Model

Company Description

Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological...

Invex Therapeutics Ltd. Financial Statement Overview

Summary

Financial performance is critically weak. The company is pre-revenue with a complete halt in income, persistent net losses, and a rapidly eroding equity base down 88% from its peak. Cash flow is consistently negative with no capital investment for growth. The only mitigating factor is a debt-free balance sheet, preventing immediate insolvency, but the overall trajectory points toward a terminal wind-down phase.

Income Statement

8Very Negative

Balance Sheet

55Neutral

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue00229.08K1.21M459.08K182.25K
Gross Profit00229.08K1.21M459.08K182.25K
EBITDA-1.54M-1.54M0-720.37K337.94K-4.14M
Net Income-1.35M-1.35M-476.87K-1.64M-7.75M-3.95M
Balance Sheet
Total Assets4.06M4.06M5.47M6.12M22.80M29.49M
Cash, Cash Equivalents and Short-Term Investments4.02M4.02M5.38M6.03M22.47M29.34M
Total Debt000000
Total Liabilities153.47K153.47K220.59K431.63K1.57M1.00M
Stockholders Equity3.91M3.91M5.25M5.69M21.23M28.48M
Cash Flow
Free Cash Flow-1.36M-1.36M-652.57K-2.44M-6.87M-3.38M
Operating Cash Flow-1.36M-1.36M-652.57K-2.44M-6.87M-3.38M
Investing Cash Flow-2.50M-2.50M0000
Financing Cash Flow000-14.00M00

Invex Therapeutics Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.09

Price Trends

50DMA0.10Negative
100DMA0.11Negative
200DMA0.11Negative

Market Momentum

MACD-0.01Positive
RSI29.85Positive
STOCH61.11Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IXC, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 29.85 is Positive, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IXC.

Invex Therapeutics Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:IXC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:TRPAU:TRP47NeutralAUD 5.86M-1.24-52.04%―32.22%-26.53%
AU:ACRAU:ACR44NeutralAUD 5.82M-6.43-45.29%―290.25%92.05%
AU:IXCAU:IXC41NeutralAUD 7.34M-4.72-31.98%――-185.71%
AU:AGNAU:AGN39UnderperformAUD 14.13M-10.38-29.22%――81.00%
AU:CMBAU:CMB39UnderperformAUD 10.30M-1.39-247.44%―-4.24%33.39%
AU:BOTAU:BOT38UnderperformAUD 27.63M-0.31-118.74%―499.47%31.20%

* Healthcare Sector Average

Performance Comparison

-50%0%50%AU:IXCAU:ACRAU:TRPAU:CMBAU:AGNAU:BOTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:IXC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:IXCInvex Therapeutics Ltd.0.09-0.03-29.17%
AU:ACRAcrux Limited0.01-0.00-33.33%
AU:TRPTissue Repair Ltd0.11-0.19-63.33%
AU:CMBRegeneus Ltd.0.35-0.16-31.37%
AU:AGNArgenica Therapeutics Ltd0.11-0.10-47.62%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.11-91.67%

Invex Therapeutics Ltd. Corporate Events

Invex Sets Shareholder Meeting as Transactions Deemed Not Fair

Nov 4, 2026

Invex Therapeutics Ltd will hold a general meeting of shareholders in Perth on 4 December 2026, with meeting materials available online through its website and the ASX platform. Shareholders may vote by proxy electronically, while printed notices and...

Invex Therapeutics Raises A$900,000 via Share Placement and Confirms Regulatory Compliance

Oct 30, 2026

Invex Therapeutics Ltd., an Australian biopharmaceutical firm, is developing Presendin, a repurposed form of exenatide intended to treat neurological conditions associated with elevated intracranial pressure, such as acute stroke and traumatic brain...

Invex Therapeutics Seeks ASX Quotation for 11.25 Million New Shares

Oct 30, 2026

Invex Therapeutics Ltd. is a biotechnology company listed on the ASX under the ticker IXC, focused on developing therapeutic products. The company operates in the life sciences sector, targeting medical conditions where novel treatments can unlock ne...

Invex Therapeutics to acquire Rekover and raise $10m for neurology pipeline

Oct 30, 2026

Invex Therapeutics has agreed to acquire New Zealand-based Rekover Therapeutics, gaining a Phase 2a clinical program repurposing nalfurafine for demyelinating diseases, including chronic optic neuropathy in multiple sclerosis. The all-scrip deal is t...

Invex Therapeutics Plans Major Equity Issue and New Performance Rights

Oct 25, 2026

Invex Therapeutics Ltd has notified the ASX of a proposed securities issue that includes 45 million new ordinary fully paid shares and a total of 91.25 million performance rights across three new classes, A, B and C. The proposed issue, structured as...

Invex Therapeutics Plans Major ASX Securities Issue

Oct 25, 2026

Invex Therapeutics has announced a proposed issue of new securities on the ASX, comprising up to 113,750,000 fully paid ordinary shares and 19,500,000 options exercisable at $0.14 and expiring on 14 December 2029. The placement or other form of issue...

Invex Therapeutics Halts ASX Trading Ahead of Acquisition and Capital Raising

Oct 21, 2026

Invex Therapeutics has requested a trading halt in its shares on the ASX, effective immediately, as it prepares to release a material announcement to the market. The halt will remain in place until either the company publishes details of a planned ma...

Invex Therapeutics Sets Date and Online Access for 2026 AGM

Oct 21, 2026

Invex Therapeutics has called its 2026 Annual General Meeting of shareholders for 20 November 2026 at 10:00am in Perth, Western Australia. The meeting notice, explanatory memorandum, annual report and proxy materials are available online via the comp...

Invex Therapeutics Sets AGM Date and Director Nomination Deadline

Sep 25, 2026

Invex Therapeutics has scheduled its Annual General Meeting for 20 November 2026, with formal meeting documentation to be provided to shareholders in October. The company has set 2 October 2026 as the deadline for director nomination submissions, sig...

Invex Therapeutics Posts Deeper Loss but Strengthens Asset Backing in 2026

Aug 31, 2026

Invex Therapeutics Ltd reported a significantly wider loss for the year ended 30 June 2026, with loss after tax attributable to members rising to $1.35 million as other income fell sharply compared with the previous year. Despite the deeper losses, t...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026